Tag: mixed_ER_PR

Articles

• ER-/PR+ breast cancer characteristics
• ER+/PR- breast cancer characteristics
• Foods to eat and avoid for ER-/PR+ patients and survivors
• Foods to eat and avoid for ER+/PR- patients and survivors
• Mixed hormone receptor (ER+/PR- or ER-/PR+) breast cancer prognosis

News

03/05/17

ER+/PR- breast cancer twice as likely to relapse as ER+/PR+ disease

06/09/11

Patients with ER-/PR+ breast cancer benefit from endocrine therapy

03/30/11

Although similar, ER+/PR- BC is more aggressive than ER+/PR+

Studies

• Survival rate and prognosis of single hormone receptor positive breast cancer. Cite
  omar a, Sadek SA. Survival rate and prognosis of single hormone receptor positive breast cancer.. Egyptian Journal of Cancer and Biomedical Research. Egyptian Knowledge Bank; 2024; 8:7-17 10.21608/jcbr.2024.284004.1352
• Epidemiology of early vs late recurrence among women with early stage estrogen receptor–positive breast cancer in the Pathways Study Cite
  Chua AV, Sheng H, Liang E, Gandhi S, Kwan ML, Ergas IJ, et al. Epidemiology of early vs late recurrence among women with early stage estrogen receptor–positive breast cancer in the Pathways Study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2024; 116:1621-1631 10.1093/jnci/djae128
• Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy Cite
  Jia L, Peng J, Sun N, Chen H, Liu Z, Zhao W, et al. Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy. BMC Cancer. Springer Science and Business Media LLC; 2024; 24 10.1186/s12885-024-12621-y
• Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study Cite
  Chua AV, Sheng H, Liang E, Gandhi S, Kwan ML, Ergas IJ, et al. Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2024; 10.1093/jnci/djae128
• Clinical Outcomes and Intrinsic Subtypes of Breast Cancer Patients with Single Hormone Receptor-positive Receiving Neoadjuvant Chemotherapy Cite
  Wang T, Wang J, Zhao W, Pan Y. Clinical Outcomes and Intrinsic Subtypes of Breast Cancer Patients with Single Hormone Receptor-positive Receiving Neoadjuvant Chemotherapy. Clinical Breast Cancer. Elsevier BV; 2024; 10.1016/j.clbc.2024.02.016
• Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status Cite
  Xu S, Murtagh S, Han Y, Wan F, Toriola AT. Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status. JAMA Network Open. American Medical Association (AMA); 2024; 7:e2353331 10.1001/jamanetworkopen.2023.53331
• Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR−/HER2+ breast cancer subtypes Cite
  Ding W, Ye D, Chen H, Lin Y, Li Z, Tu C. Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR−/HER2+ breast cancer subtypes. Breast Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s12282-023-01538-2
• Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers Cite
  Chen H, Huang F, Chen Q, Deng Y. Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers. BMC Cancer. Springer Science and Business Media LLC; 2023; 23 10.1186/s12885-023-11368-2
• Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes Cite
  Clelland EN, Rothschild HT, Patterson A, Molina-Vega J, Kaur M, Symmans WF, et al. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07059-y
• THE CLINICAL AND BIOLOGICAL SIGNIFICANCE OF ESTROGEN RECEPTOR-LOW POSITIVE BREAST CANCER Cite
  Makhlouf S, Althobiti M, Toss M, Muftah AA, Mongan NP, Lee AH, et al. THE CLINICAL AND BIOLOGICAL SIGNIFICANCE OF ESTROGEN RECEPTOR-LOW POSITIVE BREAST CANCER. Modern Pathology. Elsevier BV; 2023;:100284 10.1016/j.modpat.2023.100284
• The association of a combined healthy lifestyle with the risk of postmenopausal breast cancer subtypes in the Netherlands Cohort Study Cite
  van den Brandt PA. The association of a combined healthy lifestyle with the risk of postmenopausal breast cancer subtypes in the Netherlands Cohort Study. European Journal of Epidemiology. Springer Science and Business Media LLC; 2023; 10.1007/s10654-023-01005-4
• Estrogen receptor status heterogeneity in breast cancer tumor: role in response to endocrine treatment Cite
  Malavasi E, Giamas G, Gagliano T. Estrogen receptor status heterogeneity in breast cancer tumor: role in response to endocrine treatment. Cancer Gene Therapy. Springer Science and Business Media LLC; 2023; 10.1038/s41417-023-00618-x
• Prognosis after Local Recurrence in Patients with Early-Stage Breast Cancer Treated without Chemotherapy Cite
  Sopik V, Lim D, Sun P, Narod SA. Prognosis after Local Recurrence in Patients with Early-Stage Breast Cancer Treated without Chemotherapy. Current Oncology. MDPI AG; 2023; 30:3829-3844 10.3390/curroncol30040290
• ER–/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor Cite
  Song C, Kendi AT, Shim JY, Jung D, Kang PS, Lowe VJ, et al. ER–/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor. Breast Cancer. Springer Science and Business Media LLC; 2023; 10.1007/s12282-023-01437-6
• Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor Cite
  Scabia V, Ayyanan A, De Martino F, Agnoletto A, Battista L, Laszlo C, et al. Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor. Nature Communications. Springer Science and Business Media LLC; 2022; 13 10.1038/s41467-022-30898-0
• The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER−/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute Cite
  Gamrani S, Boukansa S, Benbrahim Z, Mellas N, Fdili Alaoui F, Melhouf MA, et al. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER−/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute. The Breast Journal. Hindawi Limited; 2022; 2022:1-9 10.1155/2022/9238804
• Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review Cite
  Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, et al. Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review. Cancers. MDPI AG; 2022; 14:1898 10.3390/cancers14081898
• De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort Cite
  Cai Y, Shao Z, Yu K. De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort. Cancer. Wiley; 2022; 10.1002/cncr.34155
• High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case series Cite
  Kunc M, Pęksa R, Cserni G, Iżycka-Świeszewska E, Łacko A, Radecka B, et al. High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case series. Pathology. Elsevier BV; 2022; 10.1016/j.pathol.2021.10.003
• Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor Cite
  Hwang K, Suh YJ, Park C, Lee YJ, Kim JY, Jung JH, et al. Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor. The Oncologist. Wiley; 2021; 26 10.1002/onco.13938
• Risk factors at five-year survival in grade 3 breast cancer: a retrospective observational study of the New Zealand population Cite
  Meharry S, Borotkanics R, Ramsaroop R, Merien F. Risk factors at five-year survival in grade 3 breast cancer: a retrospective observational study of the New Zealand population. BMC Public Health. Springer Science and Business Media LLC; 2021; 21 10.1186/s12889-021-12122-8
• Lost but Not Least—Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer Cite
  Kunc M, Popęda M, Biernat W, Senkus E. Lost but Not Least—Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer. Cancers. MDPI AG; 2021; 13:4755 10.3390/cancers13194755
• A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape Cite
  Xie P, An R, Yu S, He J, Zhang H. A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape. Journal of Translational Medicine. Springer Science and Business Media LLC; 2021; 19 10.1186/s12967-021-03076-x
• Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution’s experience in Korea Cite
  Park YH, Karantza V, Calhoun SR, Park S, Lee S, Kim J, et al. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution’s experience in Korea. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06309-1
• Outcome of breast cancer patients with low hormone receptor positivity: Analysis of a 15-year population-based cohort Cite
  Schrodi S, Braun M, Andrulat A, Harbeck N, Mahner S, Kiechle M, et al. Outcome of breast cancer patients with low hormone receptor positivity: Analysis of a 15-year population-based cohort. Annals of Oncology. Elsevier BV; 2021; 10.1016/j.annonc.2021.08.1988
• 6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer Cite
  Dar H, Johansson A, Nordensköljd A, Iftimi A, Yau C, Perez-Tenorio G, et al. 6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer. Annals of Oncology. Elsevier BV; 2021; 32:S23 10.1016/j.annonc.2021.03.020
• Dietary Inflammatory Potential and Risk of Breast Cancer: A Population-based Case-control Study in France (CECILE Study) Cite
  Hajji-Louati M, Cordina-Duverger E, Laouali N, Mancini F, Guénel P. Dietary Inflammatory Potential and Risk of Breast Cancer: A Population-based Case-control Study in France (CECILE Study). Research Square Platform LLC; 2021; 10.21203/rs.3.rs-397246/v1
• Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials Cite
  Villegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, et al. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials. European Journal of Cancer. Elsevier BV; 2021; 148:159-170 10.1016/j.ejca.2021.02.020
• Characterization of estrogen receptor-low-positive breast cancer Cite
  Fei F, Siegal GP, Wei S. Characterization of estrogen receptor-low-positive breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06148-0
• ER‐/PR+ breast cancer: a distinct entity, which is morphologically and molecularly close to triple‐negative breast cancer Cite
  Beltjens F, Molly D, Bertaut A, Richard C, Desmoulins I, Loustalot C, et al. ER‐/PR+ breast cancer: a distinct entity, which is morphologically and molecularly close to triple‐negative breast cancer. International Journal of Cancer. Wiley; 2021; 10.1002/ijc.33539
• Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival Cite
  Dauphine C, Moazzez A, Neal JC, Chlebowski RT, Ozao-Choy J. Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 27:4687-4694 10.1245/s10434-020-08898-5
• The significance of highlighting the oestrogen receptor low category in breast cancer Cite
  Poon IK, Tsang JY, Li J, Chan S, Shea K, Tse GM. The significance of highlighting the oestrogen receptor low category in breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2020; 123:1223-1227 10.1038/s41416-020-1009-1
• Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis Cite
  Wu N, Fu F, Chen L, Lin Y, Yang P, Wang C. Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis. Clinical and Translational Oncology. Springer Science and Business Media LLC; 2019; 22:474-485 10.1007/s12094-019-02149-0
• Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer Cite
  Tagliaferri B, Quaquarini E, Palumbo R, Balletti E, Presti D, Malovini A, et al. Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer. Therapeutic Advances in Medical Oncology. SAGE Publications; 2020; 12:175883592095835 10.1177/1758835920958355
• Estrogen Receptor Positive and Progesterone Receptor Negative Breast Cancer: the Role of Hormone Therapy Cite
  Dembinski R, Prasath V, Bohnak C, Siotos C, Sebai ME, Psoter K, et al. Estrogen Receptor Positive and Progesterone Receptor Negative Breast Cancer: the Role of Hormone Therapy. Hormones and Cancer. Springer Science and Business Media LLC; 2020; 11:148-154 10.1007/s12672-020-00387-1
• Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor‐positive breast cancer patients Cite
  Boland MR, Ryan ÉJ, Nugent T, Gilroy D, Kelly ME, Kennedy J, et al. Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor‐positive breast cancer patients. Journal of Surgical Oncology. Wiley; 2020; 10.1002/jso.26096
• Clinical Features and Survival of Single Hormone Receptor–Positive Breast Cancer: A Population-Based Study of 531,605 Patients Cite
  Lv M, Mao Y, Song Y, Wang Y, Liu X, Wang X, et al. Clinical Features and Survival of Single Hormone Receptor–Positive Breast Cancer: A Population-Based Study of 531,605 Patients. Clinical Breast Cancer. Elsevier BV; 2020; 20:e589-e599 10.1016/j.clbc.2020.04.010
• Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database Cite
  Fabiano V, Mandó P, Rizzo M, Ponce C, Coló F, Loza M, et al. Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database. JCO Global Oncology. American Society of Clinical Oncology (ASCO); 2020;:639-646 10.1200/jgo.19.00228
• Clinicopathological Characteristics and Breast Cancer–Specific Survival of Patients With Single Hormone Receptor–Positive Breast Cancer Cite
  Li Y, Yang D, Yin X, Zhang X, Huang J, Wu Y, et al. Clinicopathological Characteristics and Breast Cancer–Specific Survival of Patients With Single Hormone Receptor–Positive Breast Cancer. JAMA Network Open. American Medical Association (AMA); 2020; 3:e1918160 10.1001/jamanetworkopen.2019.18160
• Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer Cite
  Kang Y, Lee H, Kim YG, Han J, Kim Y, Yoo T, et al. Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer. Journal of Oncology. Hindawi Limited; 2019; 2019:1-8 10.1155/2019/7386734
• Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study Cite
  Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, et al. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. Breast Cancer. Springer Science and Business Media LLC; 2019; 27:389-398 10.1007/s12282-019-01029-3
• Long-term prognostic effect of hormone receptor subtype on breast cancer Cite
  Hwang K, Kim J, Jung J, Kim BH, Park JH, Jeon SY, et al. Long-term prognostic effect of hormone receptor subtype on breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 179:139-151 10.1007/s10549-019-05456-w
• ER−/PR+/HER2− breast cancer type shows the highest proliferative activity among all other combined phenotypes and is more common in young patients: Experience with 6643 breast cancer cases Cite
  Arena V, Pennacchia I, Vecchio FM, Carbone A. ER−/PR+/HER2− breast cancer type shows the highest proliferative activity among all other combined phenotypes and is more common in young patients: Experience with 6643 breast cancer cases. The Breast Journal. Wiley; 2019; 25:381-385 10.1111/tbj.13236
• Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer Cite
  Oudanonh T, Nabi H, Ennour‐Idrissi K, Lemieux J, Diorio C. Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer. International Journal of Cancer. Wiley; 2020; 146:2736-2745 10.1002/ijc.32621
• Hormonal therapy confers clinically relevant benefit in women with low estrogen receptor-positive breast tumor Cite
  Zhang T, Ho B, Chan P, Tan E. Hormonal therapy confers clinically relevant benefit in women with low estrogen receptor-positive breast tumor. Annals of Oncology. Elsevier BV; 2018; 29:ix9 10.1093/annonc/mdy427.004
• Only estrogen receptor “positive” is not enough to predict the prognosis of breast cancer Cite
  Ryu JM, Choi HJ, Kim I, Lee SK, Yu J, Kim J, et al. Only estrogen receptor “positive” is not enough to predict the prognosis of breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 172:627-636 10.1007/s10549-018-4948-y
• Alcohol drinking,ADH1BandADH1Cgenotypes and the risk of postmenopausal breast cancer by hormone receptor status: the Netherlands Cohort Study on diet and cancer Cite
  Hahn M, Simons CCJM, Weijenberg MP, van den Brandt PA. Alcohol drinking,ADH1BandADH1Cgenotypes and the risk of postmenopausal breast cancer by hormone receptor status: the Netherlands Cohort Study on diet and cancer. Carcinogenesis. Oxford University Press (OUP); 2018; 39:1342-1351 10.1093/carcin/bgy101
• Estrogen receptor-negative progesterone receptor-positive breast cancer – “Nobody's land“ or just an artifact? Cite
  Kunc M, Biernat W, Senkus-Konefka E. Estrogen receptor-negative progesterone receptor-positive breast cancer – “Nobody's land“ or just an artifact?. Cancer Treatment Reviews. Elsevier BV; 2018; 67:78-87 10.1016/j.ctrv.2018.05.005
• Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy Cite
  Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, et al. Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy. American Journal of Clinical Pathology. Oxford University Press (OUP); 2018; 150:34-42 10.1093/ajcp/aqy028
• Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study Cite
  Ethier J, Ocaña A, Rodríguez Lescure A, Ruíz A, Alba E, Calvo L, et al. Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study. European Journal of Cancer. Elsevier BV; 2018; 94:199-205 10.1016/j.ejca.2018.02.018
• Alcohol Consumption and Breast Cancer Risk According to Hormone Receptor Status in Japanese Women: A Case-Control Study Cite
  Takizawa Y, Kawai M, Kakugawa Y, Nishino Y, Ohuchi N, Minami Y. Alcohol Consumption and Breast Cancer Risk According to Hormone Receptor Status in Japanese Women: A Case-Control Study. The Tohoku Journal of Experimental Medicine. Tohoku University Medical Press; 2018; 244:63-73 10.1620/tjem.244.63
• The prognostic role of tumor size in early breast cancer in the era of molecular biology Cite
  Kasangian AA, Gherardi G, Biagioli E, Torri V, Moretti A, Bernardin E, et al. The prognostic role of tumor size in early breast cancer in the era of molecular biology. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0189127 10.1371/journal.pone.0189127
• Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma Cite
  Chen Z, Yang J, Li S, Lv M, Shen Y, Wang B, et al. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0182397 10.1371/journal.pone.0182397
• Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case‐Control Study in Northern and Eastern China and Implications for Chemoprevention Cite
  Wang F, Liu L, Cui S, Tian F, Fan Z, Geng C, et al. Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case‐Control Study in Northern and Eastern China and Implications for Chemoprevention. The Oncologist. Wiley; 2017; 22:1431-1443 10.1634/theoncologist.2017-0148
• Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER−/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact? Cite
  Foley NM, Coll JM, Lowery AJ, Hynes SO, Kerin MJ, Sheehan M, et al. Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER−/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?. Pathology & Oncology Research. Springer Science and Business Media LLC; 2017; 24:881-884 10.1007/s12253-017-0304-5
• Prognostic role of progesterone receptor expression in a population-based analysis Cite
  Caldarella A, Barchielli A. Prognostic role of progesterone receptor expression in a population-based analysis. Journal of Cancer Research and Clinical Oncology. Springer Science and Business Media LLC; 2017; 143:2505-2509 10.1007/s00432-017-2514-3
• Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials Cite
  van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, et al. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 167:59-71 10.1007/s10549-017-4480-5
• Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy Cite
  Petruolo OA, Pilewskie M, Patil S, Barrio AV, Stempel M, Wen HY, et al. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2556-2562 10.1245/s10434-017-5898-z
• Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer Cite
  Fujii T, Kogawa T, Dong W, Sahin A, Moulder S, Litton J, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Annals of Oncology. Elsevier BV; 2017; 28:2420-2428 10.1093/annonc/mdx397
• Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis Cite
  Chen T, Zhang N, Moran MS, Su P, Haffty BG, Yang Q. Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis. Clinical Breast Cancer. Elsevier BV; 2018; 18:1-8 10.1016/j.clbc.2017.06.005
• Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients Cite
  Yao N, Song Z, Wang X, Yang S, Song H. Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients. Journal of Breast Cancer. Korean Breast Cancer Society; 2017; 20:160 10.4048/jbc.2017.20.2.160
• Abstract 5325A: Fruit and vegetable intake and risk of breast cancer: Pooled analysis of the Nurses’ Health Study and the Nurses’ Health Study II Cite
  Farvid MS, Willett WC, Eliassen AH. Abstract 5325A: Fruit and vegetable intake and risk of breast cancer: Pooled analysis of the Nurses’ Health Study and the Nurses’ Health Study II. Epidemiology. American Association for Cancer Research; 2017; 10.1158/1538-7445.am2017-5325a
• Antiproliferative Activity of Crocin Involves Targeting of Microtubules in Breast Cancer Cells Cite
  Hire RR, Srivastava S, Davis MB, Kumar Konreddy A, Panda D. Antiproliferative Activity of Crocin Involves Targeting of Microtubules in Breast Cancer Cells. Scientific Reports. Springer Science and Business Media LLC; 2017; 7 10.1038/srep44984
• Abstract P2-05-13: Negative progesterone receptor is associate early breast cancer relapse, even among good prognosis tumors Cite
  Winner M, Rosman M, Mylander C, Jackson R, Pozo M, Wolff A, et al. Abstract P2-05-13: Negative progesterone receptor is associate early breast cancer relapse, even among good prognosis tumors. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p2-05-13
• Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index Cite
  Ono M, Tsuda H, Yoshida M, Shimizu C, Kinoshita T, Tamura K. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. Clinical Breast Cancer. Elsevier BV; 2017; 17:41-47 10.1016/j.clbc.2016.06.012
• Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer Cite
  Nordenskjöld A, Fohlin H, Fornander T, Löfdahl B, Skoog L, Stål O. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 160:313-322 10.1007/s10549-016-4007-5
• The association between China’s Great famine and risk of breast cancer according to hormone receptor status: a hospital-based study Cite
  Alimujiang A, Mo M, Liu Y, Huang N, Liu G, Xu W, et al. The association between China’s Great famine and risk of breast cancer according to hormone receptor status: a hospital-based study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 160:361-369 10.1007/s10549-016-3994-6
• Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer Cite
  Park C, Park K, Kim J, Sin Y, Park I, Cho H, et al. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. World Journal of Surgical Oncology. Springer Science and Business Media LLC; 2016; 14 10.1186/s12957-016-0999-x
• Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study Cite
  He Z, Sun J, Li F, Lin H, Wu S. Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study. OncoTargets and Therapy. Informa UK Limited; 2016;:1707 10.2147/ott.s98666
• Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype Cite
  Schroth W, Winter S, Büttner F, Goletz S, Faißt S, Brinkmann F, et al. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 155:85-97 10.1007/s10549-015-3651-5
• Prognostic Significance of Single Progesterone Receptor Positivity Cite
  Fan Y, Ding X, Xu B, Ma F, Yuan P, Wang J, et al. Prognostic Significance of Single Progesterone Receptor Positivity. Medicine. Ovid Technologies (Wolters Kluwer Health); 2015; 94:e2066 10.1097/md.0000000000002066
• Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies Cite
  Jung S, Wang M, Anderson K, Baglietto L, Bergkvist L, Bernstein L, et al. Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies. International Journal of Epidemiology. Oxford University Press (OUP); 2015; 45:916-928 10.1093/ije/dyv156
• High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer Cite
  Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, et al. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2015; 15:204-211 10.1016/j.clbc.2014.12.007
• Progesterone receptor modulates ERα action in breast cancer Cite
  Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, et al. Progesterone receptor modulates ERα action in breast cancer. Nature. Springer Science and Business Media LLC; 2015; 523:313-317 10.1038/nature14583
• Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China Cite
  Li A, Zhou S, Li M, Xu Y, Shui R, Yu B, et al. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0125067 10.1371/journal.pone.0125067
• Abstract P6-01-13: SOX10 and folate receptor alpha are frequently expressed in triple negative and progesterone receptor negative breast cancers Cite
  Hoang LL, Qi W, Yu C, Tacha D. Abstract P6-01-13: SOX10 and folate receptor alpha are frequently expressed in triple negative and progesterone receptor negative breast cancers. Poster Session Abstracts. American Association for Cancer Research; 2015; 10.1158/1538-7445.sabcs14-p6-01-13
• Short-term weight gain and breast cancer risk by hormone receptor classification among pre- and postmenopausal women Cite
  Rosner B, Eliassen AH, Toriola AT, Hankinson SE, Willett WC, Natarajan L, et al. Short-term weight gain and breast cancer risk by hormone receptor classification among pre- and postmenopausal women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 150:643-653 10.1007/s10549-015-3344-0
• Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease Cite
  Rossi S, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, Barile R, et al. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease. Clinical Breast Cancer. Elsevier BV; 2015; 15:307-312 10.1016/j.clbc.2015.03.010
• Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis Cite
  Liu J, Jiang W, Mao K, An Y, Su F, Kim BYS, et al. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 150:439-445 10.1007/s10549-015-3315-5
• Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study Cite
  Zong Y, Zhu L, Wu J, Chen X, Huang O, Fei X, et al. Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e95629 10.1371/journal.pone.0095629
• Low levels of 3,3′-diindolylmethane activate estrogen receptor α and induce proliferation of breast cancer cells in the absence of estradiol Cite
  Marques M, Laflamme L, Benassou I, Cissokho C, Guillemette B, Gaudreau L. Low levels of 3,3′-diindolylmethane activate estrogen receptor α and induce proliferation of breast cancer cells in the absence of estradiol. BMC Cancer. Springer Science and Business Media LLC; 2014; 14 10.1186/1471-2407-14-524
• Which threshold for ER positivity? a retrospective study based on 9639 patients Cite
  Yi M, Huo L, Koenig K, Mittendorf E, Meric-Bernstam F, Kuerer H, et al. Which threshold for ER positivity? a retrospective study based on 9639 patients. Annals of Oncology. Elsevier BV; 2014; 25:1004-1011 10.1093/annonc/mdu053
• Specific carotenoid intake is inversely associated with the risk of breast cancer among Chinese women Cite
  Wang L, Li B, Pan M, Mo X, Chen Y, Zhang C. Specific carotenoid intake is inversely associated with the risk of breast cancer among Chinese women. British Journal of Nutrition. Cambridge University Press (CUP); 2014; 111:1686-1695 10.1017/s000711451300411x
• Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss Cite
  Braun L, Mietzsch F, Seibold P, Schneeweiss A, Schirmacher P, Chang-Claude J, et al. Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss. Modern Pathology. Springer Science and Business Media LLC; 2013; 26:1161-1171 10.1038/modpathol.2013.60
• Intake of specific fruits and vegetables in relation to risk of estrogen receptor-negative breast cancer among postmenopausal women Cite
  Fung TT, Chiuve SE, Willett WC, Hankinson SE, Hu FB, Holmes MD. Intake of specific fruits and vegetables in relation to risk of estrogen receptor-negative breast cancer among postmenopausal women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2013; 138:925-930 10.1007/s10549-013-2484-3
• Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status Cite
  Simonsson M, Söderlind V, Henningson M, Hjertberg M, Rose C, Ingvar C, et al. Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status. Cancer Causes & Control. Springer Science and Business Media LLC; 2013; 24:929-940 10.1007/s10552-013-0169-1
• Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse Cite
  Jain S, Cohen J, Ward M, Kornhauser N, Chuang E, Cigler T, et al. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Annals of Oncology. Elsevier BV; 2013; 24:1491-1498 10.1093/annonc/mds654
• Dietary glycemic index and glycemic load and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Cite
  Romieu I, Ferrari P, Rinaldi S, Slimani N, Jenab M, Olsen A, et al. Dietary glycemic index and glycemic load and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). The American Journal of Clinical Nutrition. Oxford University Press (OUP); 2012; 96:345-355 10.3945/ajcn.111.026724
• Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010 Cite
  García Fernández A, Giménez N, Fraile M, González S, Chabrera C, Torras M, et al. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010. The Breast. Elsevier BV; 2012; 21:366-373 10.1016/j.breast.2012.03.004
• Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications: Figure 1. Cite
  Biggar RJ. Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications: Figure 1.. Clinical Cancer Research. American Association for Cancer Research (AACR); 2012; 18:2133-2137 10.1158/1078-0432.ccr-11-1389
• Low-to-moderate alcohol intake and breast cancer risk in Chinese women Cite
  Zhang M, Holman CDJ. Low-to-moderate alcohol intake and breast cancer risk in Chinese women. British Journal of Cancer. Springer Science and Business Media LLC; 2011; 105:1089-1095 10.1038/bjc.2011.302
• Association of Hormone-Related Characteristics and Breast Cancer Risk by Estrogen Receptor/Progesterone Receptor Status in the Shanghai Breast Cancer Study Cite
  Bao P, Shu XO, Gao Y, Zheng Y, Cai H, Deming SL, et al. Association of Hormone-Related Characteristics and Breast Cancer Risk by Estrogen Receptor/Progesterone Receptor Status in the Shanghai Breast Cancer Study. American Journal of Epidemiology. Oxford University Press (OUP); 2011; 174:661-671 10.1093/aje/kwr145
• Does progesterone receptor status matter in endocrine-responsive breast cancer? Cite
  Coll JM, Healy N, Coyne J, Malone C, McLaughlin R, Keane MM, et al. Does progesterone receptor status matter in endocrine-responsive breast cancer?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:e11085-e11085 10.1200/jco.2011.29.15_suppl.e11085
• Effect of dietary fiber intake on breast cancer risk according to estrogen and progesterone receptor status Cite
  Zhang C, Ho SC, Cheng S, Chen Y, Fu J, Lin F. Effect of dietary fiber intake on breast cancer risk according to estrogen and progesterone receptor status. European Journal of Clinical Nutrition. Springer Science and Business Media LLC; 2011; 65:929-936 10.1038/ejcn.2011.57
• Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer Cite
  Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Tereffe W, Woodward WA, et al. Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer. Wiley; 2010; 117:1595-1601 10.1002/cncr.25694
• A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative Cite
  Thakkar JP, Mehta DG. A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative. The Oncologist. Wiley; 2011; 16:276-285 10.1634/theoncologist.2010-0302
• Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women’s Healthy Eating and Living Study Cite
  Thomson CA, Rock CL, Thompson PA, Caan BJ, Cussler E, Flatt SW, et al. Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women’s Healthy Eating and Living Study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 125:519-527 10.1007/s10549-010-1014-9
• Discordance in hormone receptor status in breast cancer during tumor progression. Cite
  Karlsson E, Lindström LS, Wilking U, Skoog L, Johansson U, Bergh J. Discordance in hormone receptor status in breast cancer during tumor progression.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1009-1009 10.1200/jco.2010.28.15_suppl.1009
• The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors Cite
  Stuart-Harris R, Shadbolt B, Palmqvist C, Chaudri Ross H. The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors. The Breast. Elsevier BV; 2009; 18:351-355 10.1016/j.breast.2009.09.002
• Fucoidan from Laminaria cichorioides inhibits AP-1 transactivation and cell transformation in the mouse epidermal JB6 cells Cite
  Lee NY, Ermakova SP, Choi H, Kusaykin MI, Shevchenko NM, Zvyagintseva TN, et al. Fucoidan from Laminaria cichorioides inhibits AP-1 transactivation and cell transformation in the mouse epidermal JB6 cells. Molecular Carcinogenesis. Wiley; 2008; 47:629-637 10.1002/mc.20428
• Antidepressant use and breast cancer risk Cite
  Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR. Antidepressant use and breast cancer risk. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2005; 95:131-140 10.1007/s10549-005-9056-0
• Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway Cite
  Thoennissen NH, O'Kelly J, Lu D, Iwanski GB, La DT, Abbassi S, et al. Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway. Oncogene. Springer Science and Business Media LLC; 2009; 29:285-296 10.1038/onc.2009.335
• Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients Cite
  Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Research. Springer Science and Business Media LLC; 2007; 9 10.1186/bcr1639
• ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies Cite
  Finn RS, Dering J, Ginther C, Press M, Forbes J, Mackey J, et al. ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2006; 24:514-514 10.1200/jco.2006.24.18_suppl.514
• Conjugated linoleic acid intake and breast cancer risk in a prospective cohort of Swedish women Cite
  Larsson SC, Bergkvist L, Wolk A. Conjugated linoleic acid intake and breast cancer risk in a prospective cohort of Swedish women. The American Journal of Clinical Nutrition. Oxford University Press (OUP); 2009; 90:556-560 10.3945/ajcn.2009.27480
• Drinking Green Tea Modestly Reduces Breast Cancer Risk Cite
  Shrubsole MJ, Lu W, Chen Z, Shu XO, Zheng Y, Dai Q, et al. Drinking Green Tea Modestly Reduces Breast Cancer Risk. The Journal of Nutrition. Oxford University Press (OUP); 2008; 139:310-316 10.3945/jn.108.098699
• Long-term meat intake and risk of breast cancer by oestrogen and progesterone receptor status in a cohort of Swedish women Cite
  Larsson SC, Bergkvist L, Wolk A. Long-term meat intake and risk of breast cancer by oestrogen and progesterone receptor status in a cohort of Swedish women. European Journal of Cancer. Elsevier BV; 2009; 45:3042-3046 10.1016/j.ejca.2009.04.035
• Alcohol and Risk of Breast Cancer by Histologic Type and Hormone Receptor Status in Postmenopausal Women: The NIH-AARP Diet and Health Study Cite
  Lew JQ, Freedman ND, Leitzmann MF, Brinton LA, Hoover RN, Hollenbeck AR, et al. Alcohol and Risk of Breast Cancer by Histologic Type and Hormone Receptor Status in Postmenopausal Women: The NIH-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2009; 170:308-317 10.1093/aje/kwp120
• Glycemic load, glycemic index and breast cancer risk in a prospective cohort of Swedish women Cite
  Larsson SC, Bergkvist L, Wolk A. Glycemic load, glycemic index and breast cancer risk in a prospective cohort of Swedish women. International Journal of Cancer. Wiley; 2009; 125:153-157 10.1002/ijc.24310
• S-Allylcysteine reduces breast tumor cell adhesion and invasion Cite
  Gapter LA, Yuin OZ, Ng K. S-Allylcysteine reduces breast tumor cell adhesion and invasion. Biochemical and Biophysical Research Communications. Elsevier BV; 2008; 367:446-451 10.1016/j.bbrc.2007.12.175
• Dietary Phytoestrogens Are Not Associated with Risk of Overall Breast Cancer But Diets Rich in Coumestrol Are Inversely Associated with Risk of Estrogen Receptor and Progesterone Receptor Negative Breast Tumors in Swedish Women Cite
  Hedelin M, Löf M, Olsson M, Adlercreutz H, Sandin S, Weiderpass E. Dietary Phytoestrogens Are Not Associated with Risk of Overall Breast Cancer But Diets Rich in Coumestrol Are Inversely Associated with Risk of Estrogen Receptor and Progesterone Receptor Negative Breast Tumors in Swedish Women. The Journal of Nutrition. Oxford University Press (OUP); 2008; 138:938-945 10.1093/jn/138.5.938
• Long-term dietary calcium intake and breast cancer risk in a prospective cohort of women Cite
  Larsson SC, Bergkvist L, Wolk A. Long-term dietary calcium intake and breast cancer risk in a prospective cohort of women. The American Journal of Clinical Nutrition. Oxford University Press (OUP); 2008; 89:277-282 10.3945/ajcn.2008.26704
• Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort Study Cite
  Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort Study. American Journal of Epidemiology. Oxford University Press (OUP); 2009; 169:1251-1259 10.1093/aje/kwp036
• Folate Intake and Risk of Breast Cancer by Estrogen and Progesterone Receptor Status in a Swedish Cohort Cite
  Larsson SC, Bergkvist L, Wolk A. Folate Intake and Risk of Breast Cancer by Estrogen and Progesterone Receptor Status in a Swedish Cohort. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2008; 17:3444-3449 10.1158/1055-9965.epi-08-0692